
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Cardiovasc. Med. , 27 October 2022
Sec. Cardio-Oncology
Volume 9 - 2022 | https://doi.org/10.3389/fcvm.2022.1070597
This article is a correction to:
Barriers, Enablers and Strategies for the Treatment and Control of Hypertension in Nepal: A Systematic Review
A corrigendum on
Research on the mechanism and prevention of hypertension caused by apatinib through the RhoA/ROCK signaling pathway in a mouse model of gastric cancer
by Wang, W., Li, C., Zhuang, C., Zhang, H., Wang, Q., Fan, X., Qi, M., Sun, R., and Yu, J. (2022). Front. Cardiovasc. Med. 9:873829. doi: 10.3389/fcvm.2022.873829
In the published article, there was an error in the author list. Author Qingjian He was erroneously included and should have been thanked in the Acknowledgements statement instead. The corrected author list and Acknowledgements appear below.
Wenjuan Wang, Caie Li, Chenchen Zhuang, Haodong Zhang, Qiongying Wang, Xin Fan, Miaomiao Qi, Runmin Sun and Jing Yu*
We are grateful for the extremely careful and thoughtful reviews of the editor and reviewers, which greatly improved this manuscript. We also thank all members of the Cuiying Biomedical Research Center of Lanzhou University Second Hospital and Qingjian He of Zhoushan Hospital of Zhejiang Province.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: hypertension, apatinib, gastric cancer, RhoA/ROCK signaling pathway, Y27632
Citation: Wang W, Li C, Zhuang C, Zhang H, Wang Q, Fan X, Qi M, Sun R and Yu J (2022) Corrigendum: Research on the mechanism and prevention of hypertension caused by apatinib through the RhoA/ROCK signaling pathway in a mouse model of gastric cancer. Front. Cardiovasc. Med. 9:1070597. doi: 10.3389/fcvm.2022.1070597
Received: 15 October 2022; Accepted: 17 October 2022;
Published: 27 October 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Wang, Li, Zhuang, Zhang, Wang, Fan, Qi, Sun and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jing Yu, ZXJ5X2p5dUBsenUuZWR1LmNu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.